更新于 2020 年：非小细胞肺癌的治疗。
Update 2020: Management of Non-Small Cell Lung Cancer.
机构信息
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
出版信息
Lung. 2020 Dec;198(6):897-907. doi: 10.1007/s00408-020-00407-5. Epub 2020 Nov 11.
Abstract
The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.
摘要
过去十年见证了非小细胞肺癌（NSCLC）管理方面的新进展，在筛查、诊断和治疗方面取得了显著的进步。系统治疗的进展主要是由分子靶向治疗、免疫检查点抑制剂和抗血管生成药物的发展推动的，所有这些都显著改善了患者的预后，改变了这一领域的格局。本文将讨论肺癌筛查、液体活检和一线治疗中的免疫治疗的最新进展。我们讨论了最近的进展，并强调了针对具有敏感 EGFR、ALK、ROS1、RET、BRAF V600E、MET 和 NTRK 改变的 NSCLC 患者亚群的分子靶向治疗的大量新批准。
相似文献
1
Update 2020: Management of Non-Small Cell Lung Cancer.更新于 2020 年：非小细胞肺癌的治疗。
Lung. 2020 Dec;198(6):897-907. doi: 10.1007/s00408-020-00407-5. Epub 2020 Nov 11.
2
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.非小细胞肺癌：流行病学、筛查、诊断和治疗。
Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013.
3
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.针对致癌驱动的晚期非小细胞肺癌的靶向治疗：最新进展和新视角。
Expert Rev Respir Med. 2020 Apr;14(4):367-383. doi: 10.1080/17476348.2020.1714441. Epub 2020 Jan 17.
4
Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.靶向治疗与免疫治疗的进展——未来十年非小细胞肺癌的治疗将如何改变：一项叙述性综述
Ann Transl Med. 2023 Aug 30;11(10):358. doi: 10.21037/atm-22-4444. Epub 2023 Mar 23.
5
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.免疫疗法在致癌基因驱动的非小细胞肺癌患者中的疗效：一项系统评价和荟萃分析。
Ther Adv Med Oncol. 2024 Feb 27;16:17588359231225036. doi: 10.1177/17588359231225036. eCollection 2024.
6
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].[中国医学协会肺癌临床诊疗指南（2023年版）]
Zhonghua Zhong Liu Za Zhi. 2023 Jul 23;45(7):539-574. doi: 10.3760/cma.j.cn112152-20230510-00200.
7
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.非小细胞肺癌的分子靶向治疗 2014 年年度更新。
J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.
8
Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.基于循环游离 DNA 的非小细胞肺癌治疗及变异等位基因频率的影响。
Clin Lung Cancer. 2021 Jul;22(4):e519-e527. doi: 10.1016/j.cllc.2020.11.007. Epub 2020 Dec 2.
9
Biological therapies in nonsmall cell lung cancer.非小细胞肺癌的生物治疗。
Eur Respir J. 2017 Mar 2;49(3). doi: 10.1183/13993003.01520-2016. Print 2017 Mar.
10
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.非小细胞肺癌中致癌基因特异性的肿瘤突变负担、PD-L1 表达和免疫治疗结果的差异。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002891.
引用本文的文献
1
Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.单细胞RNA测序揭示RUNX3重塑非小细胞肺癌肿瘤微环境的潜在机制
Ann Surg Oncol. 2025 Sep 7. doi: 10.1245/s10434-025-18034-w.
2
Cancer-associated mesenchymal stem cell exosomes facilitate non-small cell lung cancer cell viability and invasiveness by delivering miR-182 in a FBXW7-related AKT and ERK-dependent pathway.癌症相关间充质干细胞来源的外泌体通过在FBXW7相关的AKT和ERK依赖性途径中传递miR-182来促进非小细胞肺癌细胞的活力和侵袭性。
Oncol Lett. 2025 Aug 19;30(4):487. doi: 10.3892/ol.2025.15233. eCollection 2025 Oct.
3
Curcumin and Resveratrol as Dual Modulators of the STAT3 Pathway in Lung Cancer: A Comprehensive Review.姜黄素和白藜芦醇作为肺癌中STAT3信号通路的双重调节剂：综述
Food Sci Nutr. 2025 Aug 25;13(9):e70829. doi: 10.1002/fsn3.70829. eCollection 2025 Sep.
4
Mesenchymal stem cells promote erlotinib resistance in non-small cell lung cancer through the HGF-AKT/ERK1/2-OPN pathway.间充质干细胞通过HGF-AKT/ERK1/2-OPN途径促进非小细胞肺癌对厄洛替尼的耐药性。
Am J Transl Res. 2025 Jul 15;17(7):4952-4963. doi: 10.62347/RKYL8675. eCollection 2025.
5
Druggable genome-wide Mendelian randomization integrating GWAS and eQTL/pQTL data identifies targets for lung squamous cell carcinoma.整合全基因组关联研究（GWAS）和表达数量性状基因座（eQTL）/蛋白质数量性状基因座（pQTL）数据的可药物基因组孟德尔随机化分析确定了肺鳞状细胞癌的靶点。
Sci Rep. 2025 Aug 17;15(1):30116. doi: 10.1038/s41598-025-15977-8.
6
TFAP2A promotes NSCLC malignant progression by enhancing AOC1 transcription.TFAP2A通过增强AOC1转录促进非小细胞肺癌的恶性进展。
Hereditas. 2025 Aug 14;162(1):156. doi: 10.1186/s41065-025-00524-2.
7
Enhancement of anti-programmed cell death protein-1 immunotherapy in non-small cell lung cancer using arginine and citrulline supplementation.使用精氨酸和瓜氨酸补充剂增强非小细胞肺癌中的抗程序性细胞死亡蛋白1免疫疗法。
J Thorac Dis. 2025 Jul 31;17(7):4814-4825. doi: 10.21037/jtd-2024-2109. Epub 2025 Jul 27.
8
Synergistic Effect of miR-383 and Cisplatin on Inhibition of Growth, Proliferation, and Migration of Lung Cancer Cells.miR-383与顺铂对肺癌细胞生长、增殖及迁移抑制的协同作用
Arch Iran Med. 2025 May 1;28(5):264-274. doi: 10.34172/aim.33450.
9
Study on the mechanism of gracillin inhibiting the of lung cancer NCI-H1299 cells based on MAPK signaling pathway.基于MAPK信号通路探讨藤黄菌素抑制肺癌NCI-H1299细胞增殖的机制研究 （原英文文本似乎不完整，“inhibiting the of”这里应该有缺失内容，我按照合理推测进行了补充翻译）
J Cancer. 2025 Jul 1;16(10):3048-3064. doi: 10.7150/jca.113694. eCollection 2025.
10
Cancer-associated fibroblasts-secreted lactate promotes RNA polymerase III subunit G-mediated epithelial-mesenchymal transition in non-small cell lung cancer by increasing m6A modification of zinc finger protein 384.癌症相关成纤维细胞分泌的乳酸通过增加锌指蛋白384的m6A修饰促进非小细胞肺癌中RNA聚合酶III亚基G介导的上皮-间质转化
J Cell Commun Signal. 2025 Jul 25;19(3):e70037. doi: 10.1002/ccs3.70037. eCollection 2025 Sep.
本文引用的文献
1
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.免疫治疗相关毒性管理，版本 1.2022，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020.
2
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.胸恶性肿瘤患者的 COVID-19（TERAVOLT）：一项国际、基于登记的队列研究的初步结果。
Lancet Oncol. 2020 Jul;21(7):914-922. doi: 10.1016/S1470-2045(20)30314-4. Epub 2020 Jun 12.
3
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.随机试验中 CT 容积筛查降低肺癌死亡率
N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
4
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.恩曲替尼治疗 ROS1 融合阳性非小细胞肺癌：三项 1 期-2 期临床试验的汇总分析。
Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
6
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
7
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.洛拉替尼治疗晚期 ROS1 阳性非小细胞肺癌：多中心、开放标签、单臂、1 期-2 期试验。
Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25.
8
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.PACIFIC 研究更新：放化疗后 durvalumab 治疗 III 期非小细胞肺癌的 3 年总生存数据
J Thorac Oncol. 2020 Feb;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002. Epub 2019 Oct 14.
9
Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice.电子烟烟雾可诱发小鼠肺腺癌和膀胱尿路上皮增生。
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21727-21731. doi: 10.1073/pnas.1911321116. Epub 2019 Oct 7.
10
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.雷莫芦单抗联合厄洛替尼治疗未经治疗的表皮生长因子受体突变型、晚期非小细胞肺癌患者（RELAY）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
Zotero 插件